Archive: April 2023

Second-line Treatment With CAR T-Cell Therapy for Large B-Cell Lymphoma

Abstract: The landscape for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) has continued to evolve. However, challenges continue to exist, […]

Management of Testicular Germ Cell Tumors

Abstract: Over the past half century, advancements in treatment have led to cures in an overwhelming majority of patients with testicular germ cell tumors. Astute clinical […]

The Role of Antiangiogenesis Agents in Refractory Metastatic Colorectal Cancer

H&O What are the standard treatment options for patients with refractory metastatic colorectal cancer (CRC)? SK Patients with refractory metastatic CRC typically have already received chemotherapy […]

Update on Strategies for Platinum-Resistant Ovarian Cancer

H&O How common are primary and secondary resistance to platinum therapy in ovarian cancer? BP Primary resistance to platinum occurs in approximately 20% of patients with […]

Letter From the Editor: Informed Consent?

This month, I continue my series of letters on thought-provoking clinical scenarios that have arisen during my time on the inpatient lymphoma service. The subject of […]

Highlights in Prostate Cancer From the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium

February 16-18, 2023  •  San Francisco, California and Virtual Talazoparib Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer The addition of talazoparib (Talzenna, […]

Is There Still a Role for PI3K Inhibitors in CLL?

H&O  What did the DUO trial find regarding the use of duvelisib in previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)? IWF  The […]

Momelotinib, the Next JAK2 Inhibitor?

H&O What is momelotinib and how does it work? LM Momelotinib is a selective inhibitor of Janus kinase 1 (JAK1), JAK2, and activin A receptor type […]

New Strategies for Dose Optimization in Oncology: Insights From Targeted Small-Molecule Therapies for Metastatic or Advanced Non–Small Cell Lung Cancer

H&O What types of tyrosine kinase inhibitors are used to treat metastatic or advanced non–small cell lung cancer (NSCLC)? GS There are 2 broad categories of […]

Back to Archive